FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Cardiol Therapeutics Inc. Stock AnalysisComprehensive stock analysis for Cardiol Therapeutics Inc. (CRDL) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCRDL
CRDL
Cardiol Therapeutics Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CRDL
Home🔹Stocks🔹Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc.

CRDL•NASDAQ

Cardiol Therapeutics Inc.

CRDL•NASDAQ
Market cap
$138.33M
Sentiment

Your view on CRDL

Mkt Cap
$138.33M
Sentiment
Your view
CRDL
Cardiol Therapeutics Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CRDL
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Cardiol Therapeutics Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
David G. Elsley MBA
Headquarters
2265 Upper Middle Road East, Oakville, ON, CA
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
David G. Elsley MBA
Headquarters
2265 Upper Middle Road East, Oakville, ON, CA
Description

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News